There is much evidence which highlights the involvement of the dopamine system in the pathophysiology of schizophrenia. Recently, there have been reports of detected mutations in dopamine gene receptors in genomic DNA of schizophrenia. In this study, we attempt to determine whether there is mutation in encoding dopamine receptor. The PBMC was separated from whole blood by Ficollhypaque; the total cellular RNA was extracted and the cDNA was synthesized. This process followed by real-time PCR using primer pairs specific for five dopamine receptor mRNAs and p-actin as internal control. The results show the presence of all types of dopamine receptor types in lymphocytes. The mutational analysis of the obtained PCR products for the respective dopamine receptor fragments were analyzed by sequenced capillary system. The results presented in this study confirm the high frequency of mutations in dopamine gene receptor DRD5 in schizophrenia patients. Mutational amino acid changes in dopamine gene receptors ofDR2, DR3, DR4 but not DRl are also shown. In conclusion, this is the first report of such complete mutational analyses in all dopamine gene receptors. Moreover, we found new mutations and 80% frequency of mutations in DRD5. These data further strengthen the argument for the role of dopamine gene receptor mutations in the pathogenesis of schizophrenia.
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Dopamine, together with other catecholamine such as norepinephrine, is a critical transmitter in sympathoadrenergic terminals. Such terminals lie in close contact with immune cells in lymphoid organs and there is increasing evidence which points to the ability of dopamine to affect immune cell function (1) . Dopamine receptors are integral membrane proteins that interact with G proteins to transduce dopamine stimulation into intracellular responses. Dopaminergic neurons in the human central nervous system are involved in the control of motor activity and in emotional and cognitive processes (2) . The human genome is known to contain five genes encoding the functional dopamine receptors, DRDl, DRD2, DRD3, DRD4, DRD5, and two genes highly homologous to the DRD5 encoding: the Pseudo genes (3). Human peripheral blood lymphocytes (Plsl.) express dopamine receptors and dopamine transporters and synthesize endogenous dopamine and the related catecholamine norepinephrine and epinephrine through tyrosine hydroxylase-dependent pathway (4) (5) . Interestingly, dysfunction of dopaminergic pathways in Plsl, have been reported in neurological disorders characterized by dysfunctional central dopaminergic neurotransmission, such as in the periphery (6) . However, there is much evidence that highlights the involvement of the dopamine system in the pathophysiology of schizophrenia. Moreover, there is a strong association between a potentially functional polymorphism of these genes that may playa role in the pathophysiology of schizophrenia (7) (8) (9) (10) (11) .
We conducted this study to examine whether characterizing the dopamine receptors (DRDl-DRD5) mutations at the RNA level of the dopamine gene encoding receptors is involved in the pathophysiology of schizophrenia.
MATERIALS AND METHODS
Twenty schizophrenia patients (age 20-35 years) took part in this study. Diagnosis of these patients was based on scm structured clinical interview for DSM IV. Thirty healthy individuals (age 20-35 years) were enrolled as control group. Exclusion criteria were major neurological, psychiatric, cardiovascular or endocrine disorders, infections or diseases. Written informed consent was obtained from each individual. Peripheral blood samples (4 ml) were obtained from the cubital vein and collected in cell preparation tubes containing an anti-coagulant. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque density centrifugation (Pharmacia. Uppsala, Sweden). The lymphocyte layer was collected and washed three times in phosphate buffer saline(PBS). The total mRNA was isolated from lymphocytes by RNA blood minikit (Roach, Germany), and the amount and purity of RNA were determined by spectrophotometery (12) . Dopamine receptor mRNA expression was determined by the 3' 5' fluorogenic Taqman approach (Roach, Germany). Total (RNA of 1500 ng was reverse transcribed into first-strand ComplementaryDNA( cDNA)by using randomhexamers and 2.5 units of multiscribe (recombinant Maloney murine leukemia virus). Reverse transcriptase was in a final volume of 40 III (13) . Primers for DRl, DR2, DR3, DR4, DR5 and housekeeping gene~-actin were designed using primer express software to exclude amplificationof genomic DNA and pseudo genes ( Table I) . cDNA of 75 ng was used for polymerase chain amplification (PCR). Amplification was carried out in a final volume of 25 III with 1 unit of Taq DNA polymerase (Roach, Germany). Gene amplification detection was carried out in a Realtime-PCR machine (Roach, Germany)with a Cyber green fluorogenic nucleotide to monitor cDNA amplificationby the increase in fluorescence intensity. Each PCR product of dopamine receptor (DRDl-DRD5) was sequenced by DNA sequencer ABI 3700 capillary system (Applied Biosystem, USA).
RESULTS
The aim of this study is to determine structural changes in different dopamine gene receptors (D 1-05) at RNA level on peripheral blood lymphocytes of schizophrenia patients compared to healthy individuals. In order to test this hypothesis, we examined detection of the mRNA of dopamine receptors (DRDI and DRD2) in peripheral blood lymphocytes using highly sensitive methods. We focused on the all subtypes of dopamine receptors (OROI-DRD5). Dopamine gene receptors on RNA level were performed by Real time PCR for the regions of different dopamine receptors.
Our previous study showed dopamine receptor gene-specific amplification products were different from dopamine gene receptors DRDl-DRD5 in size of PCR products in normal individuals (5) . The specificities of the obtained PCR products for the respective dopamine receptor fragments were confirmed by a capillary sequenced analysis ABI 3700 machine. Next, we sequenced all amplified dopamine gene receptor samples of patients and controls for mutational analysis. We found mutations ofdopamine gene receptors with amino acid changes in DRD2, OR03, DRD4 and ORD5 in schizophrenia patients but no mutations were detected in DRDI and in healthy individuals. peripheral blood mononuclear cells were detected. Mutational analysis data of DRD1 to DRD5 at the RNA level using capillary sequencing show structural changes in schizophrenia patients compared to healthy individuals (Table II) . Fig. 4 is a schematic diagram showing the location of mutations and the number of mutations in each dopamine receptor
Fig. 4. Schematic diagram showing the location of mutations and the number ofmutation in each dopamine receptors (DR) on peripheral blood lymphocyte (PBL) in comparison to healthy individuals and NCBI. The DRD5 with higher percentage (80%) mutation and DRDI with no mutation is less structural changes in dopamine receptors.
(DR) on peripheral blood lymphocyte (PBL) in comparison to healthy individuals and NCBI. The DRD5 had a higher percentage (80%) of mutations and DRD1 with no mutation had less structural changes in dopamine receptors. The details of mutations in each receptor (DRD1-DRD5) are shown in Table 11 .
DISCUSSION
The gene detection of the dopamine receptors is well-characterized in the brain but little research has been carried out to examine the detection in other tissues or organs. In the present study, we focused on mRNA levels. Dopamine receptor mRNA in human peripheral blood lymphocytes was investigated using the reverse transcription-polymerase chain reaction (RT-PCR). Mutations at DNA genomic level for dopamine gene receptors were reported to be involved in the etiology of schizophrenia (14) (15) . This report describes the occurrence of mutations of the encoding dopamine gene receptors (14) (15) (16) . The findings reported here suggest a primary role for mutations of dopamine receptors in causing most cases of schizophrenia. These receptors are normally synthesised in the brain, but little research has been carried out on peripheral blood lymphocytes. Dopamine-induced cytotoxicity is believed to be induced via binding to its receptor and to be activated via spontaneous, as well as metabolism-dependent, oxidation, leading to oxidative stress-induced apoptotic cell death (6, (17) (18) . However, this notion appears to be supported by accumulating evidence of altered neurotransmitter receptor expression in PBL of patients who are affected by neuropsychiatry disorders, which are believed to involve respective receptor alterations in the brain (17) (18) (19) . Disturbances in dopaminergic transmission may cause psychomotor disorders, including Parkinson's disease and schizophrenia, and the receptors are primary targets for drugs used to treat the disorders (20) (21) . This mechanism plays a critical role in neurodegenerative disorders such as Parkinson's diseases and Huntington's disease and possibly even in neurodegeneration after ischemia (22) . The comparison between our results and others indicate that we were able to show gene expression of all dopamine receptors (D 1-D5) in.an ... schizophrenia patients and normal individuals. The' difference between our methods and other methods is sensitivity for extracting RNA and amplification system by real-time peR. The results presented here provide direct evidence that human lymphocytes express dopamine Dl-like and D2-like receptors belonging to the D1 to D5 receptor subtypes. A previous study suggested that the pathophysiology of schizophrenia may be related to mutation of dopamine receptors (14) (15) (16) . Moreover, we used capillary sequencing for mutational analysis for each fragment of dopamine gene receptors (DRDI-DRD5). We found novel mutation in DRD2, DRD3, DRD4 and DRD5 but we could not find any mutation in dopamine receptor one. This is the first report of such complete mutational analysis in all dopamine gene receptors. DRD5 had the highest percentage (80%) ofthe dopamine receptors. However, there are some reports at DNA level which found mutations in DRD2 (14) . This study is the first report which indicates that mutations occur at RNA levels with amino acid changes of dopamine receptors in patients with schizophrenia. The results presented here confirm the high frequency of mutations in dopamine gene receptor DRD5 in schizophrenia patients. Moreover, we found new mutations and 80% frequency of mutations in DRD5. These data further strengthen the argument for the role of dopamine gene receptor mutations in the pathogenesis of schizophrenia. Dopamine gene receptors have no known role in peripheral blood mononuclear cells. However, other investigations have reported dopamine gene expression level (23, 25) . The mutations in schizophrenia which were found in the present study mostly showed amino acid exchange at protein level. This particular mutational change has not previously been reported. These were not found in the 30 healthy individuals tested, thus a polymorphic change is excluded.
